Jobs
-
Acton Pharmaceuticals has published positive results from a Phase 3b clinical trial of its Aerospan flunisolide HFA metered dose inhaler in the October issue of Annals of Allergy, Asthma & Immunology. The article, titled, “Linear… Read more . . .
-
Trimel Pharmaceuticals plans to present data from a recently completed Phase 2 “vibro-tactile stimulation (VTS) study” of its TBS-2 intranasal gel for the treatment of anorgasmia in women to the FDA at a meeting scheduled… Read more . . .
-
The FDA has notified Insmed Incorporated that it will continue a clinical hold on Phase 3 trials of the company’s Arikace liposomal amikacin inhalation solution for the treatment of P. aeruginosa infections in cystic fibrosis… Read more . . .
-
The US FDA has approved Boehringer Ingelheim’s Combivent Respimat tiotropium/albuterol inhalation spray for the treatment of COPD. The Combivent Respimat soft mist inhaler will replace the Combivent CFC-propelled MDI, which is to be phased out… Read more . . .
-
Inhaled pharmaceuticals developer Pulmatrix has named former Pfizer VP Michael Yeadon as an advisor to its management team and as the newest member of its scientific advisory board. Yeadon joined Pfizer in 1995 and was… Read more . . .
-
Teva UK has announced the launch of a generic CFC-free salmeterol metered dose inhaler in the UK; the product is a suspension pMDI that delivers 25 mcg per actuation. The UK granted marketing authorization for… Read more . . .
-
Gerresheimer Regensburg GmbH is looking to fill the following challenging position at its Wackersdorf site: Project Manager (m/f) Your duties: • You will manage and coordinate your project team – from the point when an… Read more . . .
-
The client is a privately held specialty biotech company focused on developing combination therapies in the respiratory, pulmonary, and asthma areas. This position will involve set up and operation of an MDI processing laboratory. The… Read more . . .
-
Alexza Pharmaceuticals and Spanish pharmaceutical company Grupo Ferrer International have formed a partnership to register, distribute, and promote the Adasuve Staccato loxapine inhaler for the treatment of agitation in patients with schizophrenia or bipolar disorder… Read more . . .
-
King’s College London will be the site of Phase 2 trials of Lightlake Therapeutics’s opioid antagonist-based nasal spray treatment for bulimia nervosa, the company has announced. Lightlake currently has Phase 2 trials underway in Finland… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.